Article Detail - JE Part B
MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis (L39467) Final LCD - Effective October 15, 2023
This Local Coverage Determination (LCD) has completed the Open Public Meeting and is now finalized under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV). Responses to comments received may be found as a link at the bottom of the final LCD.
Medicare Coverage Database (MCD) Number/Contractor Determination Number: L39467
LCD Title: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
Effective Date: October 15, 2023
Summary of LCD: This is a limited coverage policy for molecular biomarker tests to guide targeted therapy selection in Rheumatoid Arthritis (RA).
Visit the Proposed LCDs webpage to access this LCD.
Last Updated Tue, 05 Sep 2023 18:57:08 +0000